Cargando…

Bronchodilator Delivery via High-Flow Nasal Cannula: A Randomized Controlled Trial to Compare the Effects of Gas Flows

(1) Background: Aerosol delivery via high-flow nasal cannula (HFNC) has attracted increasing clinical interest. In vitro studies report that the ratio of HFNC gas flow to patient inspiratory flow (GF:IF) is a key factor in the efficiency of trans-nasal aerosol delivery. (2) Methods: In a randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jie, Chen, Yibing, Ehrmann, Stephan, Wu, Jie, Xie, Lixin, Fink, James B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539308/
https://www.ncbi.nlm.nih.gov/pubmed/34683948
http://dx.doi.org/10.3390/pharmaceutics13101655
_version_ 1784588715593564160
author Li, Jie
Chen, Yibing
Ehrmann, Stephan
Wu, Jie
Xie, Lixin
Fink, James B
author_facet Li, Jie
Chen, Yibing
Ehrmann, Stephan
Wu, Jie
Xie, Lixin
Fink, James B
author_sort Li, Jie
collection PubMed
description (1) Background: Aerosol delivery via high-flow nasal cannula (HFNC) has attracted increasing clinical interest. In vitro studies report that the ratio of HFNC gas flow to patient inspiratory flow (GF:IF) is a key factor in the efficiency of trans-nasal aerosol delivery. (2) Methods: In a randomized controlled trial, patients with a history of COPD or asthma and documented positive responses to inhaled bronchodilators in an outpatient pulmonary function laboratory were recruited. Subjects were randomized to receive inhalation at gas flow ratio settings of: GF:IF = 0.5, GF:IF = 1.0, or GF = 50 L/min. Subjects were assigned to inhale saline (control) followed by salbutamol via HFNC with cumulative doses of 0.5 mg, 1.5 mg, 3.5 mg, and 7.5 mg. Spirometry was performed at baseline and 10–12 min after each inhalation. (3) Results: 75 subjects (49 asthma and 26 COPD) demonstrating bronchodilator response were enrolled. Per the robust ATS/ERS criteria no difference was observed between flows, however using the criteria of post-bronchodilator forced expiratory volume in the first second (FEV(1)) reaching the screening post-bronchodilator FEV(1) with salbutamol, a higher percentage of subjects receiving GF:IF = 0.5 met the criteria at a cumulative dose of 1.5 mg than those receiving GF:IF = 1.0, and GF = 50 L/min (64% vs. 29% vs. 27%, respectively, p = 0.011). Similarly at 3.5 mg (88% vs. 54% vs. 46%, respectively, p = 0.005). The effective dose at GF:IF = 0.5 was 1.5 mg while for GF = 50 L/min it was 3.5 mg. (4) Conclusions: During salbutamol delivery via HFNC, cumulative doses of 1.5 mg to 3.5 mg resulted in effective bronchodilation. Applying the robust ATS/ERS criteria no difference was observed between the flows, however using the more sensitive criteria of subjects reaching post screening FEV(1) to salbutamol via HFNC, a higher number of subjects responded to the doses of 0.5 mg and 1.5 mg when HFNC gas flow was set at 50% of patient peak inspiratory flow.
format Online
Article
Text
id pubmed-8539308
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85393082021-10-24 Bronchodilator Delivery via High-Flow Nasal Cannula: A Randomized Controlled Trial to Compare the Effects of Gas Flows Li, Jie Chen, Yibing Ehrmann, Stephan Wu, Jie Xie, Lixin Fink, James B Pharmaceutics Article (1) Background: Aerosol delivery via high-flow nasal cannula (HFNC) has attracted increasing clinical interest. In vitro studies report that the ratio of HFNC gas flow to patient inspiratory flow (GF:IF) is a key factor in the efficiency of trans-nasal aerosol delivery. (2) Methods: In a randomized controlled trial, patients with a history of COPD or asthma and documented positive responses to inhaled bronchodilators in an outpatient pulmonary function laboratory were recruited. Subjects were randomized to receive inhalation at gas flow ratio settings of: GF:IF = 0.5, GF:IF = 1.0, or GF = 50 L/min. Subjects were assigned to inhale saline (control) followed by salbutamol via HFNC with cumulative doses of 0.5 mg, 1.5 mg, 3.5 mg, and 7.5 mg. Spirometry was performed at baseline and 10–12 min after each inhalation. (3) Results: 75 subjects (49 asthma and 26 COPD) demonstrating bronchodilator response were enrolled. Per the robust ATS/ERS criteria no difference was observed between flows, however using the criteria of post-bronchodilator forced expiratory volume in the first second (FEV(1)) reaching the screening post-bronchodilator FEV(1) with salbutamol, a higher percentage of subjects receiving GF:IF = 0.5 met the criteria at a cumulative dose of 1.5 mg than those receiving GF:IF = 1.0, and GF = 50 L/min (64% vs. 29% vs. 27%, respectively, p = 0.011). Similarly at 3.5 mg (88% vs. 54% vs. 46%, respectively, p = 0.005). The effective dose at GF:IF = 0.5 was 1.5 mg while for GF = 50 L/min it was 3.5 mg. (4) Conclusions: During salbutamol delivery via HFNC, cumulative doses of 1.5 mg to 3.5 mg resulted in effective bronchodilation. Applying the robust ATS/ERS criteria no difference was observed between the flows, however using the more sensitive criteria of subjects reaching post screening FEV(1) to salbutamol via HFNC, a higher number of subjects responded to the doses of 0.5 mg and 1.5 mg when HFNC gas flow was set at 50% of patient peak inspiratory flow. MDPI 2021-10-11 /pmc/articles/PMC8539308/ /pubmed/34683948 http://dx.doi.org/10.3390/pharmaceutics13101655 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Li, Jie
Chen, Yibing
Ehrmann, Stephan
Wu, Jie
Xie, Lixin
Fink, James B
Bronchodilator Delivery via High-Flow Nasal Cannula: A Randomized Controlled Trial to Compare the Effects of Gas Flows
title Bronchodilator Delivery via High-Flow Nasal Cannula: A Randomized Controlled Trial to Compare the Effects of Gas Flows
title_full Bronchodilator Delivery via High-Flow Nasal Cannula: A Randomized Controlled Trial to Compare the Effects of Gas Flows
title_fullStr Bronchodilator Delivery via High-Flow Nasal Cannula: A Randomized Controlled Trial to Compare the Effects of Gas Flows
title_full_unstemmed Bronchodilator Delivery via High-Flow Nasal Cannula: A Randomized Controlled Trial to Compare the Effects of Gas Flows
title_short Bronchodilator Delivery via High-Flow Nasal Cannula: A Randomized Controlled Trial to Compare the Effects of Gas Flows
title_sort bronchodilator delivery via high-flow nasal cannula: a randomized controlled trial to compare the effects of gas flows
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539308/
https://www.ncbi.nlm.nih.gov/pubmed/34683948
http://dx.doi.org/10.3390/pharmaceutics13101655
work_keys_str_mv AT lijie bronchodilatordeliveryviahighflownasalcannulaarandomizedcontrolledtrialtocomparetheeffectsofgasflows
AT chenyibing bronchodilatordeliveryviahighflownasalcannulaarandomizedcontrolledtrialtocomparetheeffectsofgasflows
AT ehrmannstephan bronchodilatordeliveryviahighflownasalcannulaarandomizedcontrolledtrialtocomparetheeffectsofgasflows
AT wujie bronchodilatordeliveryviahighflownasalcannulaarandomizedcontrolledtrialtocomparetheeffectsofgasflows
AT xielixin bronchodilatordeliveryviahighflownasalcannulaarandomizedcontrolledtrialtocomparetheeffectsofgasflows
AT finkjamesb bronchodilatordeliveryviahighflownasalcannulaarandomizedcontrolledtrialtocomparetheeffectsofgasflows